Abstract
Many modalities of cancer therapy induce mechanisms of treatment resistance and escape pathways during chronic treatments, including photodynamic therapy (PDT). It is conceivable that resistance induced by one treatment might be overcome by another treatment. Emerging evidence suggests that the unique mechanisms of tumor cell and microenvironment damage produced by PDT could be utilized to overcome cancer drug resistance, to mitigate the compensatory induction of survival pathways and even to re-sensitize resistant cells to standard therapies. Approaches that capture the unique features of PDT, therefore, offer promising factors for increasing the efficacy of a broad range of therapeutic modalities. Here, we highlight key preclinical findings utilizing PDT to overcome classical drug resistance or escape pathways and thus enhance the efficacy of many pharmaceuticals, possibly explaining the clinical observations of the PDT response to otherwise treatment-resistant diseases. With the development of nanotechnology, it is possible that light activation may be used not only to damage and sensitize tumors but also to enable controlled drug release to inhibit escape pathways that may lead to resistance or cell proliferation.
Similar content being viewed by others
References
R. C. Bast, B. Hennessy, G. B. Mills, The biology of ovarian cancer new opportunities for translation, Nat. Rev. Cancer, 2009, 9, 415–428.
M. T. Milano, et al., Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma, Int. J. Radiat. Oncol., Biol., Phys., 2010, 78, 1147–1155.
C. Holohan, S. Van Schaeybroeck, D. B. Longley, P. G. Johnston, Cancer drug resistance an evolving paradigm, Nat. Rev. Cancer, 2013, 13, 714–726.
D. Hanahan, R. A. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, 2011, 144, 646–674.
J. P. Thiery, H. Acloque, R. Y. Huang, M. A. Nieto, Epithelial-mesenchymal transitions in development and disease, Cell, 2009, 139, 871–890.
C. T. Jordan, M. L. Guzman, M. Noble, Cancer Stem Cells, N. Engl. J. Med., 2006, 355, 1253–1261.
S. Bao, et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, 2006, 444, 756–760.
I. Rizvi, et al., Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules, Proc. Natl. Acad. Sci. U. S. A., 2013, 110, E1974–E1983.
R. Kalluri, R. A. Weinberg, The basics of epithelial-mesenchymal transition, J. Clin. Invest., 2009, 119, 1420–1428.
B. Sennino, et al., Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors, Cancer Discovery, 2012, 2, 270–287.
S. Thomson, et al., Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition, Cancer Res., 2005, 65, 9455–9462.
A. M. Haslehurst, et al., EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer, BMC Cancer, 2012, 2, 91.
M. Izumiya, et al., Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells, Anticancer Res., 2012, 32, 3847–3853.
F. Du, et al., Acquisition of paclitaxel resistance via PI3K-dependent epithelial-mesenchymal transition in A2780 human ovarian cancer cells, Oncol. Rep., 2013, 30, 1113–1118.
S. A. Mani, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells, Cell, 2008, 133, 704–715.
M. Pàez-Ribes, et al., Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis, Cancer Cell, 2009, 15, 220–231.
S. Pennacchietti, et al., Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell, 2003, 3, 347–361.
B. Sennino, D. M. McDonald, Controlling escape from angiogenesis inhibitors, Nat. Rev. Cancer, 2012, 12, 699–709.
R. K. Jain, Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia, Cancer Cell, 2014, 26, 605–622.
D. E. J. G. J. Dolmans, D. Fukumura, R. K. Jain, TIMELINE: Photodynamic therapy for cancer, Nat. Rev. Cancer, 2003, 3, 380–387.
C. Schweitzer, R. Schmidt, Physical mechanisms of generation and deactivation of singlet oxygen, Chem. Rev., 2003, 1685–1757.
J. F. Lovell, T. W. B. Liu, J. Chen, G. Zheng, Activatable photosensitizers for imaging and therapy, Chem. Rev., 2010, 110, 2839–2857.
J. P. Celli, et al., Imaging and photodynamic therapy: mechanisms, monitoring, and optimization, Chem. Rev., 2010, 110, 2795–2838.
B. Spring, et al., Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates, Proc. Natl. Acad. Sci. U. S. A., 2014, 111, E933–E942.
M. L. Agarwal, et al., Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells, Cancer Res., 1991, 51, 5993–5996.
D. Kessel, Death pathways associated with photodynamic therapy, Med. Laser Appl., 2006, 21, 219–224.
R. Rahmanzadeh, et al., Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer, Cancer Res., 2010, 70, 9234–9242.
Q. Wan, L. Liu, D. Xing, Q. Chen, Bid Is Required in NPe6-PDT-induced Apoptosis, Photochem. Photobiol., 2007, 84, 250–257.
J. J. Reiners, P. Agostinis, K. Berg, N. L. Oleinick, D. Kessel, Assessing autophagy in the context of photodynamic therapy, Autophagy, 2010, 6, 7–18.
J. Lindsay, M. D. Esposti, A. P. Gilmore, Bcl-2 proteins and mitochondria–specificity in membrane targeting for death, Biochim. Biophys. Acta, 2011, 1813, 532–539.
B. Schellenberg, et al., Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming, Mol. Cell, 2013, 49, 959–971.
D. Kessel, Y. Luo, Photodynamic therapy: A mitochondrial inducer of apoptosis, Cell Death Differ., 1999, 6, 28–35.
J. C. Reed, et al., BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy, J. Cell. Biochem., 1996, 60, 23–32.
A. Villanueva, J. C. Stockert, M. Cañete, P. Acedo, A new protocol in photodynamic therapy: enhanced tumour cell death by combining two different photosensitizers, Photochem. Photobiol. Sci., 2010, 9, 295–297.
P. Acedo, J. C. Stockert, M. Canete, A. Villanueva, Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer, Cell Death Dis., 2014, 5, e1122.
X. Schneider-Yin, et al., Hypericin and 5-aminolevulinic acid-induced protoporphyrin IX induce enhanced phototoxicity in human endometrial cancer cells with non-coherent white light, Photodiagn. Photodyn. Ther., 2009, 6, 12–18.
E. B. Gyenge, et al., Photodynamic mechanisms induced by a combination of hypericin and a chlorin based-photosensitizer in head and neck squamous cell carcinoma cells, Photochem. Photobiol., 2013, 89, 150–162.
D. Kessel, J. J. Reiners, Enhanced Efficacy of Photodynamic Therapy via a Sequential Targeting Protocol, Photochem. Photobiol., 2014, 90, 889–895.
L. Cincotta, D. Szeto, E. Lampros, T. Hasan, A. H. Cincotta, Benzophenothiazine and Benzoporphyrin Derivative Combination Phototherapy Effectively Eradicates Large Murine Sarcomas, Photochem. Photobiol., 1996, 63, 229–237.
M. M. Gottesman, T. Fojo, S. E. Bates, Multidrug resistance in cancer: role of ATP[ndash] dependent transporters, Nat. Rev. Cancer, 2002, 2, 48–58.
V. Goler-Baron, Y. G. Assaraf, Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics, PLoS One, 2012, 7, e35487.
S. O. Gollnick, L. Vaughan, B. W. Henderson, Generation of effective antitumor vaccines using photodynamic therapy, Cancer Res., 2002, 62, 1604–1608.
M. Shams, B. Owczarczak, P. Manderscheid-Kern, D. A. Bellnier, S. O. Gollnick, Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease, Cancer Immunol. Immunother., 2015, 64, 287–297.
A. P. Castano, P. Mroz, M. R. Hamblin, Photodynamic therapy and anti-tumour immunity, Nat. Rev. Cancer, 2006, 6, 535–545.
B. Chen, B. W. Pogue, P. J. Hoopes, T. Hasan, Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy, Int. J. Radiat. Oncol., Biol., Phys., 2005, 61, 1216–1226.
V. H. Fingar, et al., Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD), Br. J. Cancer, 1999, 79, 1702–1708.
K. Kurohane, et al., Photodynamic therapy targeted to tumor-induced angiogenic vessels, Cancer Lett., 2001, 167, 49–56.
U. Schmidt-Erfurth, T. Hasan, Mechanisms of Action of Photodynamic Therapy with Verteporfin for the Treatment of Age-Related Macular Degeneration, Surv. Ophthalmol., 2000, 45, 195–214.
J. W. Snyder, W. R. Greco, D. A. Bellnier, L. Vaughan, B. W. Henderson, Photodynamic therapy: a means to enhanced drug delivery to tumors, Cancer Res., 2003, 63, 8126–8131.
B. Chen, B. W. Pogue, J. M. Luna, R. L. Hardman, P. J. Hoopes, Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications, Clin. Cancer Res., 2006, 12, 917–923.
M. Gil, et al., Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice, Br. J. Cancer, 2011, 105, 1512–1521.
K. Sano, T. Nakajima, P. L. Choyke, H. Kobayashi, Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors, ACS Nano, 2013, 7, 717–724.
O.-J. Norum, P. K. Selbo, A. Weyergang, K.-E. Giercksky, K. Berg, Photochemical internalization (PCI) in cancer therapy: From bench towards bedside medicine, J. Photochem. Photobiol., B, 2009, 96, 83–92.
P. K. Selbo, et al., Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug, J. Controlled Release, 2012, 159, 197–203.
M. Bostad, et al., Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties, J. Controlled Release, 2013, 168, 317–326.
M. Bostad, et al., Light-triggered, efficient cytosolic release of IM7-saporin targeting the putative cancer stem cell marker CD44 by photochemical internalization, Mol. Pharm., 2014, 11, 2764–2776.
A. Casas, G. Di Venosa, A. Batlle, Mechanisms of resistance to photodynamic therapy, Curr. Med. Chem., 2011, 18, 2486–2515.
C. L. Evans, et al., Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT, PLoS One, 2011, 6, e23434.
M. C. Luna, C. J. Gomer, Isolation and initial characterization of mouse tumor cells resistant to porphyrin-mediated photodynamic therapy, Cancer Res., 1991, 51, 4243–4249.
B. C. Wilson, M. Olivo, G. Singh, Subcellular Localization of Photofrin and Aminolevulinic Acid and Photodynamic Cross-Resistance in Vitro in Radiation-Induced Fibrosarcoma Cells Sensitive or Resistant to Photofrin-Mediated Photodynamic Therapy, Photochem. Photobiol., 1997, 65, 166–176.
R. A. Moorehead, S. G. Armstrong, B. C. Wilson, G. Singh, Cross-Resistance to Cisplatin in Cells Resistant to Photofrin-mediated Photodynamic Therapy, Cancer Res., 1994, 54, 2556–2559.
A. Casas, et al., Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells, Int. J. Oncol., 2006, 29, 397–405.
Z. Duan, D. E. Lamendola, Y. Duan, R. Z. Yusuf, M. V. Seiden, Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines, Cancer Chemother. Pharmacol., 2004, 55, 277–285.
D. Roberts, et al., Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells, Br. J. Cancer, 2005, 92, 1149–1158.
R. W. Robey, K. Steadman, O. Polgar, S. E. Bates, ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy, Cancer Biol. Ther., 2005, 4, 187–194.
W. Liu, et al., The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2, Clin. Cancer Res., 2007, 13, 2463–2470.
J. Morgan, J. D. Jackson, X. Zheng, S. K. Pandey, R. K. Pandey, Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy, Mol. Pharm., 2010, 7, 1789–1804.
C.-H. Yu, C.-C. Yu, Photodynamic therapy with 5-aminolevulinic acid (ALA) impairs tumor initiating and chemo-resistance property in head and neck cancer-derived cancer stem cells, PLoS One, 2014, 9, e87129.
T. A. Yap, C. P. Carden, S. B. Kaye, Beyond chemotherapy: targeted therapies in ovarian cancer, Nat. Rev. Cancer, 2009, 9, 167–181.
T. Conroy, et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N. Engl. J. Med., 2011, 364, 1817–1825.
M. G. del Carmen, et al., Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo, J. Natl. Cancer Inst., 2005, 97, 1516–1524.
I. Rizvi, et al., Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer, Cancer Res., 2010, 70, 9319–9328.
L. R. Duska, M. R. Hamblin, J. L. Miller, T. Hasan, Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo, J. Natl. Cancer Inst., 1999, 91, 1557–1563.
M. F. Zuluaga, N. Lange, Combination of photodynamic therapy with anti-cancer agents, Curr Med Chem., 2008, 15, 1655–1673.
M. Y. Nahabedian, R. A. Cohen, M. F. Contino, et al. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors, J. Natl. Cancer Inst., 1988, 80, 739–743.
G. Canti, A. Nicolin, R. Cubeddu, P. Taroni, G. Bandieramonte, G. Valentini, Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors, Cancer Lett., 1998, 125, 39–44.
C. M. Peterson, J. M. Lu, Y. Sun, et al. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice, Cancer Res., 1996, 56, 3980–3985.
J. P. Celli, N. Solban, A. Liang, S. P. Pereira, T. Hasan, Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines, Lasers Surg. Med., 2011, 43, 565–574.
B. A. Goff, M. Bamberg, T. Hasan, Photoimmunotherapy of human ovarian carcinoma cells ex vivo, Cancer Res., 1991, 51, 4762–4767.
J. M. Stommel, et al., Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies, Science, 2007, 318, 287–290.
A. D. Rhim, et al., Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma, Cancer Cell, 2014, 25, 735–747.
B. C. Özdemir, et al., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell, 2014, 25, 719–734.
M. Upreti, et al., Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics, Transl. Oncol., 2011, 4, 365–376.
J. W. Franses, A. B. Baker, V. C. Chitalia, E. R. Edelman, Stromal endothelial cells directly influence cancer progression, Sci. Transl. Med., 2011, 3, 665.
S. K. Chang, I. Rizvi, N. Solban, In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment, Clin. Cancer Res., 2008, 14, 4146–4153.
C. J. Gomer, et al., Photodynamic Therapy-mediated Oxidative Stress Can Induce Expression of Heat Shock Proteins, Cancer Res., 1996, 56, 2355–2360.
A. Ferrario, et al., Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma, Cancer Res., 2000, 60, 4066–4069.
A. Ferrario, N. Rucker, S. Wong, M. Luna, C. J. Gomer, Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response, Cancer Res., 2007, 67, 4989–4995.
D. L. Wheeler, E. F. Dunn, P. M. Harari, Understanding resistance to EGFR inhibitors-impact on future treatment strategies, Nat. Rev. Clin. Oncol., 2010, 7, 493–507.
Y. Gilaberte, et al., Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy, J. Invest. Dermatol., 2014, 134, 2428–2437.
N. Solban, et al., Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer, Cancer Res., 2006, 66, 5633–5640.
P. Nowak-Sliwinska, J. R. van Beijnum, M. van Berkel, H. van den Bergh, A. W. Griffioen, Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane, Angiogenesis, 2010, 13, 281–292.
A. Weiss, et al., Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization, J. Cell. Mol. Med., 2014, 18, 480–491.
P. Nowak-Sliwinska, et al., Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion, J. Cell. Mol. Med., 2012, 16, 1553–1562.
D. H. Gorski, et al., Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation, Cancer Res., 1999, 59, 3374–3378.
J. Tran, et al., A role for survivin in chemoresistance of endothelial cells mediated by VEGF, Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 4349–4354.
C. Justinger, et al., Increased growth factor expression after hepatic and pancreatic resection, Oncol. Rep., 2008, 20, 1527–1531.
B. Kosharskyy, et al., A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer, Cancer Res., 2006, 66, 10953–10958.
H.-C. Huang, T. Hasan, The ‘Nano’ World in Photodynamic Therapy, Aust. J. Nanomed. Nanotechnol., 2014, 2, 4.
J. F. Lovell, et al., Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents, Nat. Mater., 2011, 10, 324–332.
K. A. Carter, et al., Porphyrin-phospholipid liposomes permeabilized by near-infrared light, Nat. Commun., 2014, 5, 3546.
T. Nomoto, et al., Three-layered polyplex micelle as a multifunctional nanocarrier platform for light-induced systemic gene transfer, Nat. Commun., 2014, 5, 3545.
T. R. Wilson, et al., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, 2012, 487, 505–509.
C. Hage, et al., The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer, Cell Death Dis., 2013, 4, e627.
E. Gherardi, W. Birchmeier, C. Birchmeier, G. Vande-Woude, Targeting MET in cancer: rationale and progress, Nat. Rev. Cancer, 2012, 12, 89–103.
S. Peters, A. A. Adjei, MET: a promising anticancer therapeutic target, Nat. Rev. Clin. Oncol., 2012, 9, 314–326.
B. Sennino, T. Ishiguro-Oonuma, B. J. Schriver, J. G. Christensen, D. M. McDonald, Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice, Cancer Res., 2013, 73, 3692–3703.
L. Z. Zheng, et al., Abstract A127: Combination therapy targeting EGFR/MET crosstalk using nanotechnology improves photodynamic therapy treatment of pancreatic cancer, Mol. Cancer Ther., 2009, 8, A127–A127.
M. Bernstein and M. S. Berger, Neuro-oncology: The Essentials, Thieme, 2011.
M. T. Huggett, et al., Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer, Br. J. Cancer, 2014, 110, 1698–1704.
M. S. Eljamel, C. Goodman, H. Moseley, ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial, Lasers Med. Sci., 2008, 23, 361–367.
J. S. Friedberg, et al., Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread, J. Clin. Oncol., 2004, 22, 2192–2201.
S. M. Hahn, et al., A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis, Clin. Cancer Res., 2006, 12, 2517–2525.
K. L. Molpus, et al., Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model, Cancer Res., 1996, 56, 1075–1082.
M. A. Biel, Photodynamic Therapy Treatment of Early Oral and Laryngeal Cancers, Photochem. Photobiol., 2007, 83, 1063–1068.
V. C. K. Lo, et al., The benefits of photodynamic therapy on vertebral bone are maintained and enhanced by combination treatment with bisphosphonates and radiation therapy, J. Orthop. Res., 2013, 31, 1398–1405.
M. Mitsunaga, et al., Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules, Nat. Med., 2011, 17, 1685–1691.
T. L. Doane, C.-H. Chuang, A. Chomas, C. Burda, Photophysics of silicon phthalocyanines in aqueous media, Chem.–Eur. J. Chem. Phys., 2013, 14, 321–330.
J. D. Miller, et al., Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies, Toxicol. Appl. Pharmacol., 2007, 224, 290–299.
M. B. Vrouenraets, et al., Targeting of Aluminum (III) Phthalocyanine Tetrasulfonate by Use of Internalizing Monoclonal Antibodies Improved Efficacy in Photodynamic Therapy, Cancer Res., 2001, 61, 1970–1975.
M. B. Vrouenraets, et al., Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro, Int. J. Cancer, 2002, 98, 793–798.
D. Mew, C. K. Wat, G. H. Towers, J. G. Levy, Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates, J. Immunol., 1983, 130, 1473–1477.
W. Stummer, et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, Lancet Oncol., 2006, 7, 392–401.
I. Rizvi, et al., Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results, Isr. J. Chem., 2012, 52, 776–787.
K. Meirelles, et al., Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance, Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 2358–2363.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spring, B.Q., Rizvi, I., Xu, N. et al. The role of photodynamic therapy in overcoming cancer drug resistance. Photochem Photobiol Sci 14, 1476–1491 (2015). https://doi.org/10.1039/c4pp00495g
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/c4pp00495g